JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 56(2022) N 4 p. 616-627; DOI 10.1134/S0026893322040124 Full Text

S.V. Tillib1*, O.S. Goryainova1, A.M. Sachko1, T.I. Ivanova1,2, M.Ya. Gaas3, N.V. Vorob'ev1,4,5, A.D. Kaprin6, P.V. Shegay6

Single-Domain Antibodies Used to Pretreat the Human Urinary Proteome in Cancer Biomarker Testing

1Institute of Gene Biology, Russian Academy of Sciences, Moscow, 119334 Russia
2Tsyb Medical Radiological Research Center, National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Obninsk, Kaluga oblast, 249036 Russia
3Institute of Medicine, Peoples' Friendship University of Russia, Moscow, 117198 Russia
4Hertsen Moscow Oncology Research Institute, National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow, 125284 Russia
5Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Moscow, 119991 Russia
6National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow, 125284 Russia

*tillib@genebiology.ru
Received - 2021-11-09; Revised - 2021-12-13; Accepted - 2021-12-14

A number of single-domain antibodies (nanobodies) obtained previously to major marker blood proteins were tested as tools to preprocess urine samples from patients with bladder cancer. Nanobody-based tools demonstrated unique possibilities for noninvasive diagnostic studies along with other conventional methods, such as electrophoresis and, in prospect, mass spectrometric analysis. A testing of 22 samples from bladder cancer patients showed that the development of bladder cancer is accompanied by an increase in the urine contents of major blood proteins, including those known as potential bladder cancer biomarkers. New nanobody-based immunosorbents allow both specific enrichment and specific removal of particular antigenic proteins and subproteomes associated with them from a biological fluid. The isolation of immune complexes from the urine of a particular patient is of particular interest. An initial study of the complexes showed not only increased contents of IgA and IgG at advanced stages of the disease, but also many other components, which provide potential biomarkers of the pathological process in a particular patient. It is intended to use the approaches proposed in this work in a future larger-scale study of urine samples from patients with bladder cancer at different stages of the disease in order to identify new promising biomarkers of bladder cancer.

single-domain antibody, nanobody, urinary biomarkers, bladder cancer, immunosorbent, affinity chromatography, diagnosis



JMB-FOOTER RAS-JOURNALS